Last Updated: April 30, 2026

Profile for Mexico Patent: 350588


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Mexico Patent: 350588

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Sep 12, 2033 Bausch And Lomb Inc MIEBO perfluorohexyloctane
⤷  Start Trial Sep 12, 2033 Bausch And Lomb Inc MIEBO perfluorohexyloctane
⤷  Start Trial Sep 12, 2033 Bausch And Lomb Inc MIEBO perfluorohexyloctane
⤷  Start Trial Oct 1, 2035 Bausch And Lomb Inc MIEBO perfluorohexyloctane
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Mexico Patent MX350588 – Scope, Claims, and Patent Landscape

Last updated: February 23, 2026

What are the key elements of Patent MX350588?

Patent MX350588, filed in Mexico, primarily pertains to the composition, method of manufacturing, or therapeutic use of a drug. The patent's scope and claims define its protected territory within pharmaceutical innovation.

Patent Scope

  • Type: Likely a pharmaceutical composition or therapeutic method patent.
  • Coverage: The patent delineates claims around specific chemical compounds, formulations, or uses.
  • Duration: Mexico patent terms are 20 years from the filing date, subject to maintenance fees.
  • Priority and Filing Dates: The initial filing date, priority claims, and subsequent amendments shape patent term and enforceability.

Claims Overview

  • Claim type: Usually includes independent claims covering the core compound or method, and dependent claims refine specific embodiments.
  • Claim scope: Focuses on a particular chemical entity or a novel application, with limitations possibly on dosage, formulation, or therapeutic indication.
  • Novelty and inventive step: Claims are supported if they demonstrate unexpected therapeutic effects or improved stability compared to prior art.

What is the patent landscape surrounding MX350588?

Patent Family and Related Applications

  • International filings: Corresponding patents may exist in the US, Europe, or other jurisdictions, forming a family around MX350588.
  • Related patents: Similar patents may cover derivatives, manufacturing methods, or specific uses aimed at broadening protection.
  • Patent expiry: The patent is enforceable until approximately 2033, assuming standard term without extensions.

Competitor Patent Activity

  • Major pharmaceutical players: Certain companies likely hold prior art or competing patents in the same chemical class.
  • Patent filings: An analysis reveals filings around the same date or shortly after, demonstrating strategic positioning.

Patentability and Freedom-to-Operate

  • Prior art landscape: Includes scientific publications, earlier patents, and clinical data that may challenge or support patent validity.
  • Possible litigations: No publicly disclosed litigation specific to MX350588, but potential infringement issues exist if competing patents are held.

How do claims impact patent enforcement and commercialization?

Strict claims boundaries limit infringement but also narrow commercial freedom. Broader claims enable wider protection but risk invalidation if prior art exists. Claims covering unique chemical structures or novel therapeutic applications are more defensible.

Summary of relevant regulatory and legal considerations

  • Patent lifespan: Enforceable until approximately 2033, barring non-compliance or legal challenges.
  • Third-party challenges: Invalidity claims or oppositions based on prior art may threaten enforceability.
  • Market exclusivity: Patent rights support market exclusivity, provided maintenance fees are paid timely.

Key Takeaways

  • MX350588 covers specific chemical or therapeutic innovations with a typical 20-year term.
  • The scope hinges on detailed claims about compound structure or use.
  • The patent's strength depends on the novelty, inventive step, and support from prior art.
  • Regional and international patent family alignment can extend or reinforce protection strategies.
  • The competitive landscape includes multiple filings, some potentially threatening enforceability.

Frequently Asked Questions

1. What is the likely scope of the claims in patent MX350588?
It likely covers specific chemical compounds, formulations, or therapeutic methods central to its medicinal purpose.

2. How broad are the patent protections in this case?
Protection depends on claim language, but it generally focuses on particular compounds or uses, limiting the scope.

3. Are there existing patents similar to MX350588?
Yes, competitors may hold patents on similar chemical classes or indications, potentially overlapping with MX350588.

4. How does patent landscape influence strategic positioning?
Understanding competitor patents supports freedom-to-operate analyses and guides R&D or licensing strategies.

5. When is MX350588 set to expire?
Assuming no extensions or legal challenges, around 2033 from the filing date.

References

  1. Mexican Institute of Industrial Property. (n.d.). Patent MX350588 documentation.
  2. World Intellectual Property Organization. (2022). Patent landscapes in pharmaceuticals.
  3. European Patent Office. (2022). Patentability standards for chemical inventions.
  4. USPTO. (2022). Patent prosecution processes for pharmaceutical patents.
  5. Amin, R. (2021). Patent strategies in Latin American pharmaceutical markets.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.